Endo International plc (ENDP) Stock

About Endo International plc

Endo International plc operates as a specialty pharmaceutical firm, developing and marketing both proprietary brand-name and unbranded generic medications across the United States and global markets. Its Branded Pharmaceuticals division offers a diverse array of prescription products, notably including XIAFLEX for the treatment of Dupuytren's contracture in adults, SUPPRELIN LA to address central precocious puberty in children, NASCOBAL nasal spray for managing vitamin B12 deficiency, and AVEED for hypogonadism. Other significant branded offerings encompass QWO, an injectable solution for moderate to severe cellulite in adult women's buttocks; PERCOCET for moderate to moderately-severe pain; TESTOPEL, an implantable pellet indicated for testosterone replacement therapy (TRT); EDEX for erectile dysfunction; and LIDODERM, a topical patch designed to alleviate pain. This segment also includes other products aimed at pain management and urological conditions. The company's Sterile Injectables segment manufactures key products such as VASOSTRICT (a vasopressin injection), ADRENALIN (a non-selective adrenergic agonist), and APLISOL (a sterile aqueous solution), alongside various generic sterile injectable formulations like ertapenem and ephedrine sulfate. The Generic Pharmaceuticals segment provides a broad spectrum of formulations, including solid oral medications (both extended and immediate-release), liquids, semi-solids, transdermal patches, powders, ophthalmic solutions, and sprays. Internationally, the company's segment delivers specialized pharmaceutical products across multiple therapeutic areas, including attention deficit hyperactivity disorder, pain relief, women's health, oncology, and transplantation. Endo distributes its branded and generic offerings to a wide network of healthcare professionals and outlets, including specialty physicians, retailers, clinics, governmental bodies, individual doctors, retail and specialty pharmacies, and specialized distributors. Established in 1920, Endo International plc maintains its headquarters in Dublin, Ireland. A significant corporate development occurred on August 16, 2022, when Endo International plc and its affiliated entities voluntarily filed for Chapter 11 reorganization in the U.S. Bankruptcy Court for the Southern District of New York.

the stock is valued at a price-to-earnings (P/E) ratio of -0.15.

On profitability, Endo International plc generates a return on equity (ROE) of 45.74% — well above the market average, a sign of a high-quality business, return on capital employed of 0.22%, an operating margin of 0.53%, a net profit margin of -19.01%.

Official website: www.endo.com